Abstract
To study novel treatments for high grade gliomas (WHO grade III and IV) we need animal models of those disorders. Orthotopic tumors in mouse or rats seem at present the most reliable in vivo glioma model in order to develop specific therapies. The orthotopic tumor characteristics should yet closely mimic the human glioma features (in particular infiltrating growth and neovascularization). In this regard, glioma cell lines with stem properties (glioma stem cells – GSC) may fulfill at best those needs. Orthotopic gliomas developed from some widely used, established non-stem cell lines showing poor infiltrating capacity are not suitable. Therapeutic and diagnostic procedures recently developed using orthotopic rodent glioma tumors along their potentialities and pitfalls are analyzed.
Keywords: Brain tumor, radiotherapy, temozolomide, glioblastoma, cell cycle, resistance and in vivo.
Current Medicinal Chemistry
Title:Development of Therapeutics for High Grade Gliomas Using Orthotopic Rodent Models
Volume: 20 Issue: 26
Author(s): Guido Frosina
Affiliation:
Keywords: Brain tumor, radiotherapy, temozolomide, glioblastoma, cell cycle, resistance and in vivo.
Abstract: To study novel treatments for high grade gliomas (WHO grade III and IV) we need animal models of those disorders. Orthotopic tumors in mouse or rats seem at present the most reliable in vivo glioma model in order to develop specific therapies. The orthotopic tumor characteristics should yet closely mimic the human glioma features (in particular infiltrating growth and neovascularization). In this regard, glioma cell lines with stem properties (glioma stem cells – GSC) may fulfill at best those needs. Orthotopic gliomas developed from some widely used, established non-stem cell lines showing poor infiltrating capacity are not suitable. Therapeutic and diagnostic procedures recently developed using orthotopic rodent glioma tumors along their potentialities and pitfalls are analyzed.
Export Options
About this article
Cite this article as:
Frosina Guido, Development of Therapeutics for High Grade Gliomas Using Orthotopic Rodent Models, Current Medicinal Chemistry 2013; 20(26) . https://dx.doi.org/10.2174/0929867311320260011
DOI https://dx.doi.org/10.2174/0929867311320260011 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Editorial [Hot Topic: Mechanisms of Drug Sensitivity and Resistance in Cancer (Guest Editor: Lorraine ODriscoll)]
Current Cancer Drug Targets Yeast as a Powerful Model System for the Study of Apoptosis Regulation by Protein Kinase C Isoforms
Current Pharmaceutical Design Inducers of Heme Oxygenase-1
Current Pharmaceutical Design Physicochemical Properties that Determine Cellular Transport of Nanocarriers In Vitro and In Vivo
Current Organic Chemistry Receptor-Based Design of Cytokine Therapeutics
Current Pharmaceutical Biotechnology Modulation of Calcium Signaling in Glioblastoma Multiforme: A Therapeutic Promise for Natural Products
Mini-Reviews in Medicinal Chemistry Role of Cardiolipin in Mitochondrial Diseases and Apoptosis
Current Medicinal Chemistry Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Delivering RNA Interference to the Mammalian Brain
Current Gene Therapy Nanomedicine as a Strategy for Natural Compound Delivery to Prevent and Treat Cancers
Current Pharmaceutical Design Therapeutic Perspectives of Inhibitors of Endocannabinoid Degradation
Current Drug Targets - CNS & Neurological Disorders Disintegrins from Snake Venoms and their Applications in Cancer Research and Therapy
Current Protein & Peptide Science NUPR1 Interacts with p53, Transcriptionally Regulates p21 and Rescues Breast Epithelial Cells from Doxorubicin-Induced Genotoxic Stress
Current Cancer Drug Targets EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo
Current Cancer Drug Targets Drug-Lipid Membrane Interaction Mechanisms Revealed Through Molecular Simulations
Current Physical Chemistry Tumor Suppression by DNA Base Excision Repair
Mini-Reviews in Medicinal Chemistry MicroRNAs-Based Therapeutic Strategy for Virally Induced Diseases
Current Drug Discovery Technologies Sanguinarine: A Double-Edged Sword of Anticancer and Carcinogenesis and Its Future Application Prospect
Anti-Cancer Agents in Medicinal Chemistry Mitocans: Mitochondrial Targeted Anti-Cancer Drugs as Improved Therapies and Related Patent Documents
Recent Patents on Anti-Cancer Drug Discovery Molecular Chaperone ORP150 in ER Stress–related Diseases
Current Pharmaceutical Design